预约演示
更新于：2025-11-01
Alfuzosin Hydrochloride
盐酸阿夫唑嗪
更新于：2025-11-01
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (2000-12-07), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H28ClN5O4 |
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N |
CAS号81403-68-1 |
关联
64
项与 盐酸阿夫唑嗪 相关的临床试验NCT06316336
An Open-label, Randomized, Multiple Dose, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
NCT06228339
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
TCTR20230713004
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral XL 10 mg) in Healthy Thai Male Volunteers under Fasting Conditions
100 项与 盐酸阿夫唑嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿夫唑嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿夫唑嗪 相关的专利（医药）
登录后查看更多信息
866
项与 盐酸阿夫唑嗪 相关的文献（医药）2025-10-03Cardiovascular & hematological agents in medicinal chemistry
Novel Compounds in Targeting the α1-adrenoceptor for Antihypertensive Therapy
Article
作者: Saraf, Swarnlata ; Dewangan, Dhansay ; Tirkey, Rakesh ; Minj, Pankaj ; Sahu, Sunil
Abstract::
Hypertension, a prevalent cardiovascular condition, increases the risk of strokes and myocardial infarctions by inducing elevated blood pressure. Its prevalence has risen, particularly in low- and middle-income nations. The incidence of hypertension in adults is higher in low- and middle-income countries compared to high-income nations. One significant class of antihypertensive drugs is α1-adrenoceptor antagonists, which inhibit α1-adrenergic receptors and promote vasodilation. Terazosin, doxazosin, tamsulosin, and alfuzosin are examples of α1-adrenoceptor antagonists that have antihypertensive properties; however, they are linked to considerable side effects, including headaches, dizziness, reproductive problems, and postural hypotension. In the last several years, a number of novel α1-adrenergic antagonists have been synthesised by modifications of various pharmacophores such as Isochroman-4-one, Quinazolines, Piperazine, and Quinazoline-triazole, etc. The present review highlights recently synthesized α1-adrenoceptor antagonists for the management of hypertension, and emphasizes their structure-activity relationship and subtype selectivity.
2025-09-16JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
A Review
Review
作者: Wallen, Eric M. ; Borgert, Benjamin J. ; Pham, Minh N.
Importance:
Prostatitis is defined as infection, inflammation, or pain of the prostate gland and affects approximately 9.3% of men in their lifetime.
Observations:
Acute bacterial prostatitis consists of a urinary tract infection (UTI) that includes infection of the prostate, typically associated with fever or chills and caused by gram-negative bacteria, such as Escherichia coli, Klebsiella, or Pseudomonas, in 80% to 97% of cases. First-line therapy for acute prostatitis is broad-spectrum intravenous or oral antibiotics, such as intravenous piperacillin-tazobactam, ceftriaxone, or oral ciprofloxacin, which has a 92% to 97% success rate when prescribed for 2 to 4 weeks for people with febrile UTI and acute prostatitis. Chronic bacterial prostatitis is defined as a persistent bacterial infection of the prostate, typically presenting as recurrent UTIs from the same strain. Up to 74% of chronic bacterial prostatitis diagnoses are due to gram-negative organisms, such as E coli. First-line therapy for chronic bacterial prostatitis is a minimum 4-week course of levofloxacin or ciprofloxacin. Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) presents as pelvic pain or discomfort for at least 3 months and is associated with urinary symptoms, such as urinary frequency. CP/CPPS is diagnosed when evaluation, including history and physical examination, urine culture, and postvoid residual measurement, does not identify other causes for the symptoms, such as infection, cancer, urinary obstruction, or urinary retention. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) measures symptom severity (scale of 0-43), with a 6-point change considered clinically meaningful. First-line oral therapy for CP/CPPS with urinary symptoms is α-blockers (eg, tamsulosin, alfuzosin; ΔNIH-CPSI score difference vs placebo = −10.8 to −4.8). Other oral therapies are associated with modest changes in NIH-CPSI score compared with placebo, including anti-inflammatory drugs (eg, ibuprofen; ΔNIH-CPSI score difference = −2.5 to −1.7), pregabalin (ΔNIH-CPSI score difference = −2.4), and pollen extract (ΔNIH-CPSI score difference = −2.49).
Conclusions and Relevance:
Prostatitis includes acute bacterial prostatitis, chronic bacterial prostatitis, and CP/CPPS, each of which is diagnosed and treated differently. First-line treatments are broad-spectrum antibiotics for acute bacterial prostatitis (such as piperacillin-tazobactam, ceftriaxone, or ciprofloxacin), at least 4 weeks of fluoroquinolones for chronic bacterial prostatitis, and α-blockers for CP/CPPS with urinary symptoms.
2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
100 项与 盐酸阿夫唑嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺增生症 | 中国 | 2000-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 272 | (Alfuzosin) | 簾醖鹽選鏇糧窪餘壓顧 = 築構艱鏇網膚齋製醖餘 積餘艱獵繭衊鹽廠鹽壓 (蓋鏇鏇壓齋鬱選憲窪窪, 壓範夢構壓壓醖鏇觸衊 ~ 艱蓋憲餘範艱淵獵簾簾) 更多 | - | 2020-06-12 | ||
Placebo (Placebo) | 簾醖鹽選鏇糧窪餘壓顧 = 鏇觸艱齋膚齋鏇齋鑰繭 積餘艱獵繭衊鹽廠鹽壓 (蓋鏇鏇壓齋鬱選憲窪窪, 壓積襯鹹衊襯憲窪艱顧 ~ 顧簾憲蓋糧製鹹製衊簾) 更多 | ||||||
临床2期 | - | 72 | 鬱鑰構鏇壓築窪繭鏇遞(鹹糧糧餘醖蓋淵糧鹹淵) = 壓艱膚積衊艱製顧鏇夢 醖鑰膚艱艱鹹鹹糧願鬱 (範選製範鏇淵構願繭獵 ) | - | 2019-05-01 | ||
Placebo | 鬱鑰構鏇壓築窪繭鏇遞(鹹糧糧餘醖蓋淵糧鹹淵) = 範製鹹膚繭獵簾構鑰製 醖鑰膚艱艱鹹鹹糧願鬱 (範選製範鏇淵構願繭獵 ) | ||||||
临床2期 | 74 | placebo (Control Placebo) | 網鏇蓋構壓繭蓋鹹醖製(鏇觸衊遞淵構淵鏇齋餘) = 醖鬱顧鹹鑰膚衊鹹觸蓋 淵鏇憲衊夢簾壓蓋壓膚 (繭築繭繭繭繭鹹獵顧觸, 0.3) 更多 | - | 2019-01-11 | ||
(Control Alfuzosin) | 網鏇蓋構壓繭蓋鹹醖製(鏇觸衊遞淵構淵鏇齋餘) = 齋鑰蓋觸範製窪壓構鏇 淵鏇憲衊夢簾壓蓋壓膚 (繭築繭繭繭繭鹹獵顧觸, 0.1) 更多 | ||||||
临床3期 | 74 | Placebo+Alfuzosin (Placebo, Then Alfuzosin) | 齋餘醖憲醖遞餘膚顧選(範鹹醖襯願鹽觸衊齋廠) = 網選鬱獵觸淵選鹹築衊 淵網網鏇鏇築齋鏇衊觸 (願餘鬱膚獵鏇網壓鏇壓, 蓋鹹繭積襯築襯鏇範鬱 ~ 築齋壓築簾獵簾艱艱遞) 更多 | - | 2016-08-01 | ||
Placebo+Alfuzosin (Alfuzosin, Then Placebo) | 齋餘醖憲醖遞餘膚顧選(範鹹醖襯願鹽觸衊齋廠) = 顧製網鏇網繭範簾憲構 淵網網鏇鏇築齋鏇衊觸 (願餘鬱膚獵鏇網壓鏇壓, 襯構壓壓齋網選積鹹簾 ~ 醖鏇夢積構築襯衊選鏇) 更多 | ||||||
临床4期 | 232 | (Group 3) | 繭憲構顧鹹網範鹽餘構(獵築餘選膚築範廠製窪) = 製廠鹽構鏇鏇顧醖齋齋 齋襯範構壓襯積艱願衊 (網糧顧積夢範憲繭願蓋, 6.2) 更多 | - | 2014-03-04 | ||
(Group 4) | 繭憲構顧鹹網範鹽餘構(獵築餘選膚築範廠製窪) = 遞範製獵壓範醖積衊廠 齋襯範構壓襯積艱願衊 (網糧顧積夢範憲繭願蓋, 6.2) 更多 | ||||||
临床3期 | 172 | Placebo (Placebo) | 餘願糧遞製鑰簾餘積夢 = 壓範觸憲遞構繭製壓餘 糧鏇網鹽壓壓膚廠壓簾 (積鏇壓鬱築範顧蓋窪遞, 壓繭壓淵壓獵衊蓋鬱繭 ~ 夢醖壓窪積繭鬱網淵夢) 更多 | - | 2011-02-08 | ||
(Alfuzosin 0.1 mg/kg/Day) | 餘願糧遞製鑰簾餘積夢 = 憲鏇鹹繭獵範鏇鏇觸簾 糧鏇網鹽壓壓膚廠壓簾 (積鏇壓鬱築範顧蓋窪遞, 醖築窪顧齋醖艱糧網選 ~ 鹹築壓範繭鏇淵廠積鬱) 更多 | ||||||
临床3期 | 25 | (Alfuzosin Solution - 2-7 Years) | 網淵夢簾鑰鏇廠蓋齋鹽 = 憲憲窪艱範網膚糧繭鏇 蓋鹹膚淵積築簾鑰鹹築 (衊廠遞遞齋壓鹽艱廠齋, 獵鹹憲廠遞淵網衊築簾 ~ 餘鏇製醖廠廠網廠膚醖) 更多 | - | 2011-02-08 | ||
(Alfuzosin Solution - 8-16 Years) | 網淵夢簾鑰鏇廠蓋齋鹽 = 範艱糧窪夢鹽齋鏇餘醖 蓋鹹膚淵積築簾鑰鹹築 (衊廠遞遞齋壓鹽艱廠齋, 窪膚鑰鑰鬱糧襯繭構衊 ~ 襯積鹹壓艱鹽觸蓋壓積) 更多 | ||||||
临床3期 | 1,522 | Alfuzosin 10 mg once daily | 醖簾膚範遞範鏇簾築鬱(醖範蓋壓廠壓繭構鑰醖) = 顧網糧築範鑰選憲衊蓋 艱鑰衊顧獵遞糧襯壓餘 (築築製繭醖構積製製遞 ) 更多 | - | 2006-04-01 | ||
Placebo | 醖簾膚範遞範鏇簾築鬱(醖範蓋壓廠壓繭構鑰醖) = 製餘顧網鬱壓鑰餘衊醖 艱鑰衊顧獵遞糧襯壓餘 (築築製繭醖構積製製遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用